Table 4. Disease outcomes and costs associated with MenACWY vaccination at 14 months only and MenACWY vaccination at 14 months and 12 years.

	14 months	14 months +12 years		Δ
Disease outcome
Meningococcal cases
All	46		40	−6
With skin scarring	1		1	0
With amputations	0		0	0
With neurological sequelae	3		3	0
Deaths	3		3	0
Life years (disc.)	17,225,124		17,225,133	9
QALYs (disc.)	15,482,017		15,482,029	12
Costs (€) (discounted)
Total costsa	9,356,182		21,039,738	11,683,555
Direct costsb	9,336,046		19,576,633	10,240,587
Vaccination costsc	8,729,539		19,123,583	10,394,044
Indirect vaccination costsd	1,959		1,450,110	1,448,151
Productivity losses	20,809		1,463,778	1,442,968

Δ = difference between the vaccination strategies in respectively disease outcome and costs,

disc. = discounted, QALY = quality adjusted life year.

^aThe total sum of all costs (including vaccination costs).

^bDirect costs: total costs minus costs due to productivity losses.

^cVaccination costs: costs of the vaccine plus administration and overhead costs.

^dIndirect vaccination costs: costs for the treatment of side effects of the vaccination. Productivity losses due to vaccination and side effects are included in ‘productivity losses’.